[The efficacy of intralymphatic use of antiblastic drugs].
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002415:Cats; D003520:Cyclophosphamide / Q000008:administration & dosage; D004285:Dogs; D005260:Female; D006048:Gold Colloid, Radioactive / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy; D007272:Injections, Intralymphatic; D008207:Lymphatic Metastasis / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D009581:Nitrofurans / Q000008:administration & dosage; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011437:Propylamines / Q000008:administration & dosage; D012004:Rectal Neoplasms / Q000188:drug therapy; D013852:Thiotepa / Q000008:administration & dosage
D000970:Antineoplastic Agents; D006048:Gold Colloid, Radioactive; D009581:Nitrofurans; D009588:Nitrogen Mustard Compounds; D011437:Propylamines; D003520:Cyclophosphamide; D013852:Thiotepa
Ob éffektivnosti vnutrilimfaticheskogo primeneniia antiblasticheskikh preparatov.